SIX · ROP.SW
Roche Holding AG
CHF 402.20+CHF 0.50 (+0.12%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
Loading market information…
NASDAQ · VECT · USD
Stock price, earnings
Quote as of Jul 7, 2023, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
VectivBio Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow VectivBio Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 402.20+CHF 0.50 (+0.12%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
CHF 134.14+CHF 1.84 (+1.39%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 0.68% below the high.
$38.53-$0.38 (-0.97%)
Edgewise Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.56% below the high.
$20.67-$0.81 (-3.78%)
Tyra Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.15% below the high.
$10.66-$0.40 (-3.66%)
Design Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.23% below the high.
$7.69-$0.29 (-3.62%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.07% below the high.
$19.80-$0.71 (-3.44%)
Tectonic Therapeutic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.92% below the high.
$0.61-$0.01 (-1.3%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.56% below the high.
